Deschloroketamine
Deschloroketamine is a dissociative research chemical of the arylcyclohexylamine class. Structurally analogous to ketamine but lacking the chlorine substitution on its phenyl ring, it produces dissociative, anesthetic, and hallucinogenic effects. It is reported to be more potent than ketamine with a longer duration of action.1 The substance is primarily available through online research chemical vendors as a designer drug.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Distortions
Auditory
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Deschloroketamine has not been the subject of formal pharmacological studies. Based on its arylcyclohexylamine structure and its dissociative effect profile, it is presumed to act primarily as an NMDA receptor antagonist. No other specific receptor mechanisms have been elucidated.
Pharmacokinetics
No formal pharmacokinetic data is available for deschloroketamine. Very little is known about its metabolism, distribution, or elimination in humans.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateWith repeated use, deschloroketamine may present a moderate addiction risk, carries meaningful abuse potential, and may lead to psychological dependence. Reports also describe compulsive redosing during use.
Physical
LowWhen addiction develops, cravings and withdrawal effects may occur upon sudden cessation of use, though the severity and nature of physical withdrawal symptoms are not well-characterized.
Toxicity
Chronic frequent use may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pelvic and bladder pain, hematuria, and incontinence; these effects appear to occur to a lesser extent than with ketamine and can be avoided by limiting use to occasional rather than daily or weekly consumption.
Antibacterial properties have been speculated but only minimally investigated. If real, prolonged frequent use could potentially disrupt gut microbiome or affect immune function, though this has not been confirmed as a concern at reasonable low-frequency use levels.
Psychosis Risk
Dissociatives including DCK carry a risk of adverse psychological reactions such as mania, hypomania, delusions, and confusion. Mania is listed as a potential acute cognitive effect. Risk may be elevated when combined with stimulants.
History & Culture
Discovery and Synthesis
Deschloroketamine was first described in a 1966 patent filed by Calvin Stevens at Parke-Davis in Michigan. Stevens, who is also credited with the synthesis of ketamine and phencyclidine, outlined the preparation methods for this structurally related
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
References
Citations
- Frison G, Zamengo L, Zancanaro F, Tisato F, & Traldi P. (2016-01-15). Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance. Rapid Communications in Mass Spectrometry, 30(1), 151-160. https://doi.org/10.1002/rcm.74251
- (1966-05-31). Aminoketones and methods for their production. Google Patents. https://patents.google.com/patent/US3254124/en1
- (1998-09-22). Use of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, fungal, virus or protozoan infections as well as for immunomodulation. Google Patents. https://patents.google.com/patent/US5811464/en1
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Deschloroketamine article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
